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Aim: In hemodialysis patients, the need to have intercurrent sodium and water intake removed by ul-
traﬁltration increases disease burden through the symptoms and signs that occur during hemodialysis
(HD). This added burden may be mitigated by reduction of dietary sodium intake. The National Kidney
Foundation (NKF) recommends 2400 mg of dietary sodium daily for patients on HD, and the American
Heart Association (AHA) suggests 1500 mg, evidence is lacking, however, to support these recommen-
dations in HD. Moreover, little is known about the relationship of speciﬁc levels of dietary sodium intake
and the severity of symptoms and signs during ultraﬁltration. Our goal will be to determine the effects of
carefully-monitored levels of sodium-intake as set forth by the NKF and AHA on symptoms and signs in
patients undergoing (HD).
Methods: We designed a three-group (2400 mg, 1500 mg, unrestricted), double blinded randomized
controlled trial with a sample of 42 HD participants to determine whether 1. Symptom proﬁles and
interdialytic weight gains vary among three sodium intake groups; 2. The effect of HD-speciﬁc variables
on the symptom proﬁles among the three groups and 3. Whether total body water extracellular volume
and intracellular volume measured with bioimpedance varies across the three groups. We will also
examine the feasibility of recruitment, enrollment, and retention of participants for the ﬁve-day inpa-
tient stay.
Conclusion: Curbing dietary sodium intake may lead to improvement in intradialytic symptom amelio-
ration and potential for better long-term outcomes. Generating empirical support will be critical to
ascertain, and espouse, the appropriate level of sodium intake for patients receiving HD.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Over 636,000 people in the United States suffer from end stage
renal disease (ESRD) and many of these require thrice weekly he-
modialysis (HD) treatments to remove kidney wastes, re-establish
electrolyte balance, and remove excess volume [1]. Given the pro-
gressive nature of chronic kidney disease and intermittent nature of
HD rather than a continuous homeostatic control of volume, the
loss of normal kidney function leads to hypervolemia, azotemia,
and electrolyte imbalance [2e4].
Interdialytic weight gain (IDWG) describes the increase in bodySchool of Nursing, 418 Curie
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Inc. This is an open access article uweight due to water accumulation from metabolism, dietary so-
dium and volume intake [5,6] between dialysis sessions. Dietary
sodium intake, and possibly dialysate sodium from HD, stimulate
osmoreceptors to create thirst and encourage volume intake,
increasing total body water (TBW) and therefore IDWG [7,8].
Excessive IDWG necessitates more volume removal during HD and
causes symptoms such as pain, cramps, hypotension, nausea and
vomiting during HD treatments [9]. Studies have shown that large
ﬂuctuations in IDWG not only results in an increase in extracellular
volume, and therefore blood pressure, but also increases strain on
the cardiovascular system, and symptoms such as abdominal
bloating, swelling of the extremities, and, in extreme cases, dys-
pnea and cardiac arrhythmias that can lead to pulmonary edema
and heart failure respectively. Cardiovascular disease is the leading
cause of death for ESRD patients. Extrapolating from the beneﬁts of
salt restriction in studies conducted on hypertensive and diabeticnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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restricting dietary sodium intake in the ESRD patient population
will improve the health, survival, and quality of life for many HD
patients.
The National Kidney Foundation (NKF) suggests a total of
2400 mg of dietary sodium a day. The Dietary Guidelines for
Americans 2010 and American Heart Association (AHA) suggest
1500 mg a day for persons with hypertension or kidney disease. To
date, there are no randomized controlled trials in the ESRD patient
population to substantiate these recommendations [10]. The liter-
ature demonstrates that, while lifestyle modiﬁcations in the ESRD
patient population such as ﬂuid restriction, are essential to survival
and increased quality of life, adherence is poor [11e18]. Non-
adherence estimates vary from 20 to 78% and lack of adherence
translates into high morbidity and mortality [19e22].
Medicare is the principal payer for ESRD management via HD
therapy and in 2012 total ESRD Medicare spending was 28.6 billion
and was 5.6% of total Medicare spending [23]. ESRD patients are
twice as likely asmembers of the general Medicare population to be
rehospitalized. In this regard 38% of the ESRD Medicare expendi-
ture was spent on in-patient care. Over a third of the all-cause
rehospitalizations among HD patients occurs among patients be-
tween 20 and 44 years of age. For ESRD patients that are hospi-
talized for cardiovascular-related events over half of
rehospitalizations are due to ESRD and the highest rates for reho-
spitalization are acute myocardial infarction and congestive heart
failure. Conﬁdently recommending a guideline that is supported by
substantiated careful clinical research could lead to better out-
comes and fewer rehospitalizations.
2. Methodology
2.1. Study design
We designed a three-group, double-blinded, parallel, random-
ized controlled trial planning to enroll 42 patients with ESRD. Pa-
tients will be assessed for the effects of sodium intake on HD
symptom proﬁles for consumption of 1500 mg or 2400 mg a day
and compared to a control group that consumes an unrestricted
amount. Given the small-to-moderate effect of sodium intake
group membership on IDWG, symptom proﬁles, and body
composition (R2 change ¼ 0.02.13 [Cohen's f2 ¼ 0.02.15]), a
sample of 42 participants (14 per group), and an alpha of .05, we
estimate our power to be <70%, thus, the initial study will primarily
serve to demonstrate feasibility. Given the low power, we will
examine our data for meaningful trends in terms of clinical sig-
niﬁcance in the outcomes, anticipating that this preliminary work
will provide information about the effect size for the larger study
that will follow. The study and all associated materials are currently
approved by the Institutional Review Board of the University of
Pennsylvania and written informed consent will be obtained from
each participant prior to study enrollment.
2.2. Sample
Patients who are undergoing maintenance HD, will be stable for
at least three months, age 21 years or older, and able to read or
write English to be eligible for this study. If patients are not able to
read or write, if they do not speak English or intend to move out of
the area or change dialysis centers within the following six months
they are not considered for recruitment. Exclusion criteria includes
a terminal illness, life expectancy less than 12 months, planning to
receive a living donor transplant during the study period, or a class
III or IV NYHA heart failure. Pregnant patients or those with an
internal deﬁbrillator, or pacemaker, will not able to participatebecause of safety reasons given the proposed use of BIS measure-
ments [24,25]. Patients with cognitive impairment and those un-
able to provide informed consent will also be excluded.
2.3. Study recruitment
Participants will be recruited from a single academic, tertiary
care center in Pennsylvania and three urban DaVita Dialysis Cen-
ters. Participants will be recruited with the approval of attending
nephrologists, and advanced practice nurses aided by dialysis unit
advertisement. IRB-approved ﬂyers will be posted throughout the
clinic and dialysis center waiting areas, so patients can self-refer to
the study. Potential participants will need physician approval for
participation. A nominal stipend will be provided to participants
prorated for each day of participation, with a completion bonus at
the conclusion of the ﬁve-day admission.
2.4. Randomization
Participants will be randomized to one of three sodium intake
groups (unrestricted, 1500 mg a day or 2400 mg a day) upon
admission using a pseudo-randomizer. Fifty thick, opaque enve-
lopes are prepared (42 participants and 8 in case of withdrawal or
refusal), each indistinguishable from the others. Using a pseudo
generator in S plus 8.0, a list of 50 digits of 1,2, or 3 to represent
control group (CG), 1500 mg Na daily, and 2400 mg Na daily,
respectively. When an eligible participant is available for admission
another envelope is drawn from the ﬁle, beginning with envelope
#1 for the ﬁrst participant. Group Assignment will only be known
to dietary staff who prepare and measure the food, not to the
subject or Investigators.
2.5. Primary outcomes
Our study aims will be to determine whether reduction in
sodium-intake to guideline recommendation results in the less
IDWG and the fewer symptoms experienced while on dialysis.
Symptoms are characterized utilizing the 5 subscales of the Kidney
Disease Quality of Life Survey: Physical Component, Mental
Component, Burden of Kidney Disease, Symptoms/Problems, and
Effects of Kidney Disease on Daily Life (long term assessment, last 3
months) [26,27] We will also conduct the Palliative Care Outcome
Scale-Renal. This is a short self-report survey to evaluate the
symptom severity in advanced chronic illness, speciﬁcally ESRD,
and end of life in the short-term (last three days). Higher scores in
the former reﬂect higher quality of life, while higher scores in the
later reﬂect increased symptom burden. Weight will be measured
daily with IDWG calculated at DaVita Dialysis Centers as per stan-
dard care. Body composition (TBW, ECF, ICF) is measured using the
Impedimed Imp_SFB7 (Carlsbad, CA.), which was shown to have
adequate reliability has been demonstrated in ESRD, in regard to
TBW r ¼ 0.92, r ¼ 0.73 for body cell mass; validated by application
of dilution methods [24e27]. Daily sodium intake totals will be
calculated by certiﬁed nutritionists in the research centermetabolic
kitchen. Participants are given an allotment of food for the day and
remaining items deducted from the daily total to result in near
exact determination of total mgs consumed per day. All HD-related
data is extracted from dialysis center electronic medical records.
2.6. Secondary outcomes
We are undertaking this feasibility phase as there are no dietary
studies of this type to benchmark against. Thus, we deemed it
useful to gather data to support a larger study with power based on
effect sizes and variability form this feasibility endeavor. Other
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successfully recruit and retain participants for the duration of the
admission, in addition to assessing the soundness of our study
design and ability to measure body composition changes in the
time period allotted.
2.7. Intervention
Potential participants will be screened for inclusion/exclusion
criteria and provide written informed consent and HIPAA release
forms. They will be admitted to the inpatient research unit in an
academic, tertiary care center immediately following a HD session
at their usual dialysis center on either Monday or Tuesday. Partic-
ipants will remain in the inpatient unit for ﬁve days and four nights
and be randomly assigned to one of three sodium intake groups.
Weinberger and Fineberg [28] demonstrated stability in responses
to changes in sodium intake with a three-day protocol. We sur-
mised from this that three full days of controlling diet would yield
similar results. One group will be randomized to consume 1500 mg
of sodium a day, a second group 2400 mg of sodium a day and
control group will consume an unrestricted amount of sodium per
day (these participants will select off of a restaurant style menu and
their sodium intake calculated based on consumption). All meals
and snacks will be controlled and provided by the metabolic
kitchen at the research unit, and uneaten remnants are accounted
for by the nutrition staff. Only the sodium content of the food
differed between participants.
Admission data will include a medical history, a review of cur-
rentmedications, food andmedication allergies, baseline vital signs
(temperature, blood pressure, orthostatic blood pressures, heart
rate, oxygenation by pulse oximetry, and respiratory rate), height,
weight, body composition by bioimpedance spectrometry (BIS), the
Kidney Disease Quality of Life-36 (KDQOL-36), a dietary habits
survey, and baseline deuterium oxide measurement.
Patients will attend their regular HD sessions on days 1, 3 and 5
of the study period. Blood pressure is taken prior to HD (after a 5-
min rest) and immediately after HD. Blood pressure will be
measured in three consecutive measurements 2 min apart, and the
mean systolic and diastolic values are recorded. HD days (specif-
ically days 3 and 5) will also include Palliative Care Outcome
Survey-Renal (PCOS) administered by study personnel after return
from HD to the research unit.
Three days prior to admission and on day 4 of the study
deuterium oxide (05. mg/kg deuterium oxide: D2O) will be
administered in a fasting state. Serum samples for deuterium oxide
enrichment will be obtained immediately prior to and after HD.
Body volume compositionwill be measured at the same time IDWG
and blood pressure will be abstracted from the DaVita Dialysis
records.
3. Data collection
Study subjects will be assigned an identiﬁcation number uponDay 1 Day 2 Day 3 Day 4 Day 5
Baseline Data Collection X
KDQOL-36 X
POS X X X
Dietary Habits Questionnaire X
BIS X X X X X
Deuterium Oxide Sampling X X X
Blood Pressure X X X X X
IDWG X X Xenrollment that will be used to track data throughout the study
period. Data will be collected on IRB approved source documents,
entered into REDCap, and double keyed to ensure accuracy. Source
documents will be kept in participant charts that contain consents,
tax documents, POS, symptom proﬁle surveys, bioimpedance
measurement data, and screeningmaterials. Charts will be kept in a
locked ﬁle cabinet within a locked location accessible only to
research personnel.4. Data analysis
To determine the effect of the randomized sodium intake group
membership on symptom proﬁles and IDWG, a series of multiple
regression analyses will be conducted with each symptom proﬁle
score (KDQOL or POS) and the IDWG as dependent variables with
sodium intake group membership (CG, sodium intake of 1500 mg,
sodium intake of 2400 mg) and covariates (e.g., age, gender, race,
duration of illness) as independent variables. Similarly, multiple
regression analyses will be conducted to determine if dialysis
speciﬁc procedures (ultraﬁltration rate, total volume removed) and
intradialytic symptoms are related to sodium intake; and to
determine the variation of body composition based on sodium
intake.5. Methodological considerations and limitations
This will be the ﬁrst study of its kind, therefore there are no
other studies to benchmark against. Empirical data to determine
the optimal length of stay in the controlled environment of the
research unit is unavailable, thus, we chose a convenience duration
of 5 days to ensure a reasonable sodium steady-state has been
achieved. Furthermore, the admission was not truly a complete 5-
day stay. Day 1 and Day 5 were partial days and so there may
need to be an extension of length of stay to adequately achieve
steady-state.
Although measures will be taken to minimize errors associated
with dietary sodium intake, not all human error can be completely
eradicated. Participants may request items or attempt to consume
items not in their daily allotment of food; nursing staff may want to
oblige participants' desires, and therefore ongoing education and
reeducation will certainly be necessary. Food preparation will be
challenging and require nutritionists to prepare handmade meals
ahead of time and thus obtaining dietary preferences/needs
required coordination and we will institute a “preadmission” visit
to this end and to address any other dietary concerns; i.e. diabetes.
Similarly, the extended admission hours present unique issues for
stafﬁng and ensuring that study protocol requirements will be met
consistently. Study staff will work in shifts, however, overnight and
early morning hours will not be covered requiring nursing staff to
be vigilant about the study protocol and the study PI to be vigilant
about spot checks, and the integrity of data collected.
The study design might have been simpliﬁed to the inclusion of
only two groups. The current dietary sodium intake recommen-
dations set forth by two inﬂuential agencies, along with the IOM
report, predicated that the intake recommendations with the most
controversy be included in the trial. Additionally, the literature
repeatedly suggests that HD patients are consuming, alongwith the
general American population far more sodium than recommended.
In order to maintain rigor, demonstrate a full picture of symptoms
experienced at various of levels of sodium intake, and a change in
those symptom proﬁles with or without reduction in sodium intake
and to what degree of reduction, the inclusion of a “free-range”
control group was also warranted.
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This is the ﬁrst RCT, to our knowledge, to be conducted con-
trolling for sodium intake in ESRD patients. This pilot study affords
us the opportunity to obtain quality preliminary data that dem-
onstrates the feasibility of such a randomized controlled trial with
this particular set of parameters.
7. Conclusion
Determining the appropriate sodium intake guideline recom-
mendation to ameliorate interdialytic symptom proﬁles, is likely to
result in improved morbidity and mortality for ESRD patients. The
results of this study will be the ﬁrst empiric step towards this goal.
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